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ABSTRACT 
Background: Tuberculosis (TB) is an ancient disease still kills more than two million people every 
year, despite the fact that a cure has been available for over 50 years. Some antituberculosis agents 
cause hepatotoxicity as a major adverse drug reaction.  
Objectives: This study was designed to investigate rifampicin, isoniazid and pyrazinamide 
induced-hepatotoxicity among TB patients in Sudan. 
Methods: Sudanese in-patients (n=57) their ages ranged between 15 to 76 years, with active 
pulmonary tuberculosis and normal pretreatment liver function, received rifampicin (10 
mg/Kg/day), isoniazid (5 mg/Kg/day) and pyrazinamide (20 mg/Kg/day) daily for  two months, 
were involved in this study. Liver function test was performed for each patient separately at week 8, 
9 and 10, to assess direct and indirect bilirubin, alanine aminotransferase, alkaline phosphatase, 
aspartate aminotransferase, albumin and total protein levels. 
Results: Liver function tests revealed that 10 (17.5%) patients had high serum total bilirubin level, 
whereas 46 (80.7%) of them showed significant alteration in direct (conjugated) bilirubin level. 
Five (8.7%) and 23 (40.3%) patients demonstrated increased serum level of alanine 
aminotransferase and alkaline phosphatase respectively.  Moreover, 15 (26.3%) of the treated 
patients experienced higher serum levels of aspartate aminotransferase. Hepatotoxicity and 
symptoms of liver failure occurred in 9 (15.7%) patients, which necessitate treatment 
discontinuation. Thirty eight (66.6 %) of the treated patients developed alteration in serum albumin 
level, whereas slight alteration in total protein level was found in 12 (21%) of the TB patients. 
Conclusions: Biochemical investigations and clinical monitoring of patients treated with 
antituberculosis drugs are essential to decrease hepatotoxicity of these agents. 
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n 24 march 2005 (world day of 
tuberculosis), the International Union 
Against Tuberculosis and Lung Disease 
(IUATLD) reported that: tuberculosis is an 
ancient diseasestill kills more than two 
million people every year despite the fact that 
a cure has been available over 50 years. With 
nearly 25000 people developed tuberculosis 
on daily basis, approximately one-third of the 
world’s    population   (2 billion)   people   are 
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infected with tuberculosis. Of these numbers 
95% of the new cases occur in developing 
countriesThe impact of tuberculosis produces 
greater determinant in the developing 
countries because it generally affects the most 
economically active segment of the 
population, those between the age of 15 and 
54
1
.WHO reports stated that tuberculosis  
is a global emergency since it is one of the 
most widely prevalent infectious diseases 
affecting millions of human population in 




There are different treatment regimens used 
for tuberculosis therapy
3
. The WHO 
recommended a regimen (6-9 months) 
consisting of rifampicin, isoniazid, 
pyrazinamide and/or ethambutol for the initial 
I 
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two months followed by a further four months 
of rifampicin and isoniazid
4
. Although most 
patients tolerate antituberculosis drugs, some 
agents may cause adverse effects and many 
drug interactions including gastrointestinal 
disturbances and hypersensitivity reactions
3
. 
The incidence and severity of unwanted 
reaction are related to dosage and duration of 
administration. The major adverse effect of 
rifampicin, isoniazid and pyrazinamide is 
hepatotoxicity
[4]
. The patient receiving these 
drugs may often undergo liver function test 
for determination of aspartate 
aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase 
(ALP) and bilirubin levels. The enzyme AST 
is mainly a liver enzyme and in general the 
increase in serum levels of both AST and 
ALT indicates liver cell damage associated 
with the two drugs, isoniazid and rifampicin. 
This is confirmed by the high level of the 
enzyme ALP that occurs mainly in the 
disorders of the liver,biliary tract and bone
5, 6
.  
In Sudan the treatment of tuberculosis follows 
the Sudan TB module guidelines for both 
adult and children. It consists of two phases, 
the initial phase in which a daily use of at 
least three drugs (rifampicin, isoniazid, 
pyrazinamide or ethambutol) for two months 
and the continuation phase using two drugs 
(rifampicin and isoniazid) in full sensitive 
cases for a further four months. Ethambutol 
can be omitted from the regimen if the 
resistance to isoniazid is low
7
. Streptomycin 
is scarcely used if resistance to isoniazid has 




Indian studies for patients with pulmonary 
tuberculosis treated with rifampicin and 
isoniazid showed that these drugs induced 
hepatotoxicity.  This adverse drug reaction is 
common and it is potentially fatal
9, 10
. 
The present study was an attempt to 
investigate the hepatotoxicity of 
antituberculosis therapy in TB patients in 
some hospitals of Khartoum State.  
Materials Methods 
Study population  
This study was conducted at Elshaab, 
Abuaanga and Suba Hospitals, Khartoum 





 October 2006. Three hundred 
patients were selected to participate in this 
study and were diagnosed with positive 
sputum smear tuberculosis test (Zn. test) and 
had chest X-ray findings compatible with 
active pulmonary tuberculosis. All the 
patients had pretreatment evaluation clinically 
especially for evidence of liver disease, 
history of alcoholism or concomitant drug 
therapy. 
The TB patients fulfilled the following 
criteria: Patients suffering from previous 
hepatic disease or infected with hepatitis virus 
as well as those with high alcohol 
consumption or using hepatotoxic drugs 
and/or drugs that may enhance hepatotoxicity, 
pregnant ladies and children below 15 years 
old were excluded (n=243). This study was 
approved by the ethics committees in the 
three hospitals.  
Treatments regimen and blood sampling 
The patients were treated daily with isoniazid 
5 mg/kg/day (GMC, Ltd, Sudan, maximum 
dose 300 mg/day), rifampicin 10 mg/Kg/day 
(GMC, Ltd, Sudan, maximum dose 600 
mg/day) and pyrazinamide 20 mg/Kg/day 
(Microlabs Pharmaceutical, India, maximum 
dose 2000 mg/day) for two months. Liver 
function tests were performed at week 8, 9 
and 10 for each patient separately.  
The TB patients were monitored clinically as 
well as biochemically. The treatment of the 
participants was under control in all cases. All 
treatment was self-administered; patients 
were continuously evaluated for signs and 
symptoms of adverse events by especialists of 
chest diseases and assessed for adherence to 
treatment. 
After 2 months of continuous treatment, 5 ml 
of blood were drawn from the orbital plexus 
by nontoxic, pyrogen free sterile disposable 
syringe at week 8, 9 and 10 for each patient 
separately.  
The blood samples were collected in lithium 
heparin containers and after 5 minutes of 
centrifugation (2000 rpm) the obtained 
supernatant serum samples were frozen at -
20C
o
 until they were analyzed for total liver 
function test using Roche Hitachi 912 
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Chemistry Analyzer (F. Hoffmann Roche Ltd, 
Switzerland). This apparatus was found in 
research and laboratory unit, Khartoum 
teaching hospital. It is mainly used for 
analysis of various body fluids and it is fully 
automated, computerized and performed 
potentiometric and photometric assays.  It 
consists of photometric measuring system, 
analytical processing unit, screen and printer. 
The analyzer characteristics included 200 
photometric tests per hour and refrigerated 
storage for 40 reagent containers. For serum 
determination of bilirubin, alanine 
aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, albumin and total 
protein levels, 0.5 ml of serum sample for 
each patient was placed in the apparatus 
separately registered in the screen and results 
were printed within 10 minutes for each 
parameter. 
Statistical analysis 
The data were subjected to completely 
randomized design. Analysis of results were 
carried out using simple t-test and mean 
separations were conducted to test significant 
difference of groups with the aid of SPSS 
computer program version 14. 
Results 
The participants in this study were 57 
patients, their ages ranged between 15 to 76 
years and the mean age being 39.7 ± 18.3 
years and weighing 61.6 ± 11.3 kg. The male-
to-female ratio of those patients was 2.4:1 
(Table 1). Before treatment the liver function 
tests for all patients, were normal.  
The present study revealed that 10 (17.5%) 
patients received antituberculosis 
chemotherapy showed increases in serum 
total bilirubin level, ranged between 1.2-1.6 
mg/dl, slightly greater than the normal level 
of total bilirubin (0.1-1 mg/dl). Also there 
was significant alteration in serum direct 
(conjugated) bilirubin level in 46 (80.7%) 
patients, ranged between 0.1-0.5 mg/dl, while 
normal limit is 0.0-0.25 mg/dl
6, 11
 (Table 1). 
Accordingly, small proportion of patients 
developed jaundice. These findings agreed to 
the results published by Sanches, et al., 
(2004) who described the hepatoxicity of both 
isoniazid and rifampicin that required a 




Table 1: Number of patients with altered liver enzymes 
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Serum alanine aminotransferase (ALT) level  
was altered in 5 (8.7%) patients (Table 1), 
showed increases in the enzyme level, ranged 
between 52-92 U/L, exceeding the normal 
range of ALT (0.0-49 U/L). ALT is 
commonly used as a way of screening for 
liver problems; however,   elevated   level   of  
 
ALTdoes not automatically mean that 
medical problems exist. Fluctuation  of   ALT 
level is normal overthe course of the day, and 




Table 1 indicated remarkable alteration in 
serum alkaline phosphatase (ALP) level in 23
 TajEldin et al.                 Investigation of Hepatotoxicity of Anti TB Medications in some Hospitals
 
© Sudan JMS Vol. 8, No.2. June 2013      102 
 (40.3%) of the treated patients. Most of them 
(n=19) demonstrated an obvious increases in 
the enzyme level and their concentrations 
ranged between 41-333 U/L, higher than the 
normal level of serum alkaline phosphatase 
(26-111 U/L). There was considerable 
alteration in serum aspartate  
aminotransferase (AST) level in 15 (26.3%) 
patients (Table 1), their serum levels ranged 
between 51-389 U/L, above the normal level 
(0-46 U/L). Hepatotoxicity and symptoms of 
liver failure occurred in 9 (15.7%) patients, 
which necessitate treatment discontinuation. 
It was reported that, in an intension to 
treatment analysis if 5% of the total patients 
developed grade three hepatotoxicity (>5 
times of the normal range this showed the 




As showed in Table 1, elevation in the serum 
total albumin developed in 38 (66.6%) of the 
treated patients. Of those 24 (63.1%) 
experienced increases in albumin level, their 
serum levels ranged between 4.4-4.8 g/dl 
while the normal range is 3.8-44 g/dl. 
The alteration in the serum total protein 
(albumin, globulin and fibrinogen) level 
occurred in 12 (21%) of the treated patients 
was shown in Table 1. Six (10.5%) of them 
showed increases in serum total protein level 






Tuberculosis is a major health problem 
throughout the world, especially in the 
developing countries. The chronic use of 
antituberculosis medication is usually 
accompanied with hepatotoxic adverse 
reactions. The present study was carried out 
to evaluate the hepatotoxic effects of some 
drugs used in tuberculosis therapy particularly 
rifampicin, isoniazid and pyrazinamide.  
 The obtained results demonstrated 
that,hepatotoxicity as an adverse drug 
reaction was evident, common  and  
potentially fatal. There were considerable 
changes in serum levels of bilirubin, ALT, 
ALP and AST, which are relatively common 
during antituberculosis chemotherapy, and 
may signify true organ toxicity. It appeared 
that for patients who are going to develop 
hepatotoxicity eventually, any elevation in 
AST levels three times greater than the upper 
limit of normal may easily become five times 
the upper limit of normal in due course. In the 
present study hepatotoxicity and symptoms of 
liver failure occurred in 9 (15.7%) patients, 
which necessitate treatment discontinuation. 
According to the American Thoracic Society 
recommendations antituberculosis drugs 
should be stopped when the serum 
transaminase level reaches three times the 
upper limit of normal for patients developing 
symptoms of hepatitis. The symptoms of 
gastrointestinal discomfort like anorexia, 
nausea, vomiting, epigastric distension, right 
upper abdominal discomfort, as well as other 
symptoms such as malaise and weakness are 
important
15
 and the more relevant signs such 
as jaundice and hepatomegaly.  
Combination of isoniazid with rifampicin and 
pyrazinamide increases the risk of 
antituberculosis medications induced 
hepatotoxicity
16-20
 when compared with 
isoniazid monotherapy used for tuberculosis 
prophylaxis. Rifampicin is a drug of elative 
low toxicity when compared to isoniazid, 
although it is a potent liver metabolizing 
enzymes inducer that may enhance isoniazid 
hepatotoxicity
21
. Pyrazinamide also is most 
hepatotoxic antituberculosis medication like 
isoniazid. It was reported that, the mechanism 
of hepatotoxicity has been considered to be 






Biochemical investigations and clinical 
monitoring of patients treated with 
antituberculosis drugs are essential to identify 
and/or to avoid hepatotoxicity of these agents. 
Treatment regimens with fewer potentially 
hepatotoxic agents might be beneficial for 
therapy of patients with tuberculosis. Patients 
counseling and education helps to minimize 
the risk of hepatotoxicity. Close clinical 
monitoring is essential and routine liver tests 
screening should be carried out before 
commencement of antituberculous drugs. 
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Patients with underlying hepatic abnormality 
pose a significant problem, since most drug-
induced hepatotoxicity occurs within the 
initial two months of therapy, therefore closer 
monitoring at weekly/biweekly intervals for 
example, is recommended. 
The early identification and modification of 
antituberculosis treatment are crucially 
needed for patients with increased risk of 
antituberculosis induced-hepatotoxicity, and 
hence reducing the morbidity and mortality. 
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